Slingshot members are tracking this event:
Development of Varlilumab and Nivolumab (Opdivo) to Advance to Phase 2 Study - Open Enrollment to Begin Q2 of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Apr 18, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Varlilumab, Nivolumab, Opdivo, Multiple Solid Tumors